Figures computed from official regulatory filings — .
Ownershipinsiders 12.84% · institutions 19.71%
In EUR · as of Oct 26, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for THX PHARMA only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for rare neurological disease, as well as TX01 for the treatment of Gaucher disease and Niemann-Pick type C diseases. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonyme in September 2025. The company was founded in 2013 and is headquartered in Lyon, France.
Market information source · Oct 26, 2026
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| JULIEN VEYS | BuyD (derivative) | $16.9K | First in 12mo | AMF |
| JULIEN VEYS | BuyD (derivative) | $9.6K | AMF |
| JULIEN VEYS | SellD (derivative) | $15.9K | AMF |
| JULIEN VEYS | SellD (derivative) | $17.6K | AMF |
| JULIEN VEYS | BuyD (derivative) | $15.4K | AMF |
| JULIEN VEYS | SellD (derivative) | $10.1K | AMF |
| Mathieu Charvériat | Exercise | $78.2K | AMF |